Pharming Group N.V. (PHGUF.PK,PHGUF.OB,PHAR,PHARM.AS) said Thursday that its total revenues for fiscal 2025 are expected to be around $376 million, thus exceeding an upwardly revised outlook range of $365 million to $375 million given in November 2025. The company added that the 2025 revenues are 27 percent higher than that recorded in fiscal 2024.
The Dutch biopharmaceutical company attributed the revenue growth to the continued growth of RUCONEST and rising demand for Joenja, mainly helped by patient uptake in the U.S. and ongoing geographic expansion.
According to Pharming Group, fiscal 2025 operating expenses are expected to fall within the earlier estimated range of $304 million to $308 million.
Looking ahead, the company said that it expects sustained revenue growth and further progress across its clinical pipeline in fiscal 2026. Pharming Group will release its fourth-quarter and full-year 2025 financial results on March 12.
Commenting on the preliminary results, Fabrice Chouraqui, Chief Executive Officer, said, "W delivered a strong year in 2025, driven by robust demand for our commercial assets and renewed financial discipline. RUCONEST continued to grow in an increasingly competitive environment, while Joenja uptake erated with rising U.S. patient demand and international expansion."
On the OTC Markets, PHGUF.PK ended Wednesday's trading at $1.6500.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.